India set to lead biopharma innovation wave: Minister Anupriya Patel
Synopsis
India has put a ₹10,000 crore bet on becoming a global biologics hub by 2047 — and the Biopharma Shakti Mission is the centrepiece. With PLI schemes already cutting API import dependence, Minister Anupriya Patel's address at ASSOCHAM's Pharma Summit signals a deliberate pivot from generic-medicine dominance to next-generation biopharmaceutical leadership.
Key Takeaways
Minister Anupriya Patel addressed ASSOCHAM's Pharma Summit & Awards 2026 in New Delhi on 11 June 2026 .
The government has announced a ₹10,000 crore Biopharma Shakti Mission targeting at least 100 biologics by 2047 .
PLI schemes have boosted domestic manufacturing of APIs and critical drugs, reducing import dependence.
India aims to become a global hub for advanced therapies, novel biologics, and next-generation healthcare solutions.
Department of Pharmaceuticals Secretary Manoj Joshi and ASSOCHAM Past President Anil K.
Agarwal also addressed the summit.
Union Minister of State for Health & Family Welfare and Chemicals & Fertilisers Anupriya Patel on Thursday, 11 June 2026 declared that India is well-positioned to lead the next wave of biopharmaceutical innovation, citing the government's push on domestic manufacturing, research, and a newly announced ₹10,000 crore Biopharma Shakti Mission. Her remarks came at ASSOCHAM's Pharma Summit & Awards 2026 in New Delhi.
India's Pharma Ambition
Patel framed India's pharmaceutical ascent as both an economic and strategic imperative. 'India's journey towards becoming Atmanirbhar in pharmaceuticals and biotechnology is not only an economic objective but also a strategic necessity,' she said. The minister noted that Production-Linked Incentive (PLI) schemes have significantly boosted domestic manufacturing of active pharmaceutical ingredients (APIs) and critical drugs, reducing import dependence across key pharmaceutical inputs.
The Biopharma Shakti Mission
Describing biopharmaceuticals as India's 'next strategic frontier,' Patel outlined the recently announced ₹10,000 crore Biopharma Shakti Mission. The mission targets the development of at least 100 biologics by 2047 and aims to position India as a global hub for advanced therapies, novel biologics, and next-generation healthcare solutions — while sustaining its established leadership in affordable generic medicines. 'The future of pharma will belong to those who innovate, collaborate and build for the world, and India is ready to lead,' Patel stated.
Government and Industry Voices
Manoj Joshi, Secretary of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, said the Indian pharmaceutical industry is entering a new phase of growth driven by innovation, quality, regulatory excellence, and global competitiveness. ASSOCHAM Past President Anil K. Agarwal said the sector is at a defining moment where innovation, regulatory excellence, and collaborative partnerships can help establish India as a global leader in advanced healthcare solutions.
Call for Multi-Stakeholder Collaboration
Patel called for deeper coordination among government agencies, industry, academia, startups, investors, regulators, and healthcare institutions to strengthen research capabilities, manufacturing resilience, and global quality standards. This comes amid growing international scrutiny of pharmaceutical supply chains, where India's role as the 'pharmacy of the world' carries both opportunity and responsibility.
What's Next
With the Biopharma Shakti Mission now announced, attention will turn to implementation timelines, funding disbursement, and regulatory frameworks for biologics. Industry bodies are expected to engage closely with the Department of Pharmaceuticals on sectoral guidelines in the coming months.
Point of View
Which risks becoming a long-range aspiration rather than an accountable programme. The real test will be whether the ₹10,000 crore is disbursed against verifiable R&D milestones or absorbed into infrastructure spending with limited innovation output. India's generic dominance was built on cost, not patents — making the biologics pivot structurally harder than the rhetoric suggests.
NationPress
8 Aug 2026
Frequently Asked Questions
What is the Biopharma Shakti Mission announced by the Indian government?
The Biopharma Shakti Mission is a government initiative with a ₹10,000 crore outlay aimed at developing at least 100 biologics by 2047 and positioning India as a global hub for advanced therapies and novel biologics. It was highlighted by Minister Anupriya Patel at ASSOCHAM's Pharma Summit on 11 June 2026.
Why is India focusing on biopharmaceutical innovation now?
India has established dominance in generic medicines and API manufacturing, and the government views biopharmaceuticals as the next strategic frontier for long-term growth. Minister Patel described the shift as both an economic objective and a strategic necessity for self-reliance.
How have PLI schemes helped India's pharmaceutical sector?
Production-Linked Incentive schemes have significantly enhanced domestic manufacturing of active pharmaceutical ingredients (APIs) and critical drugs, reducing India's dependence on imports across key pharmaceutical inputs, according to Minister Anupriya Patel.
Who spoke at ASSOCHAM's Pharma Summit & Awards 2026?
Key speakers included Minister of State Anupriya Patel, Department of Pharmaceuticals Secretary Manoj Joshi, and ASSOCHAM Past President Anil K. Agarwal, all of whom emphasised innovation, regulatory excellence, and global competitiveness.
What is India's long-term goal in the pharmaceutical sector?
India aims to become a global hub for advanced therapies, novel biologics, and next-generation healthcare solutions by 2047, while maintaining its leadership in affordable generic medicines. The Biopharma Shakti Mission is the primary vehicle for this ambition.
